Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
CSII's Cash-to-Debt is ranked higher than
94% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CSII: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CSII' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.11  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
CSII's Equity-to-Asset is ranked higher than
65% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. CSII: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
CSII' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.4  Med: 0.51 Max: 0.94
Current: 0.71
-1.4
0.94
Piotroski F-Score: 6
Altman Z-Score: 10.66
Beneish M-Score: -3.66
WACC vs ROIC
19.85%
-68.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -14.78
CSII's Operating Margin % is ranked lower than
63% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. CSII: -14.78 )
Ranked among companies with meaningful Operating Margin % only.
CSII' s Operating Margin % Range Over the Past 10 Years
Min: -60.63  Med: -21.58 Max: 3.82
Current: -14.78
-60.63
3.82
Net Margin % -14.74
CSII's Net Margin % is ranked lower than
64% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. CSII: -14.74 )
Ranked among companies with meaningful Net Margin % only.
CSII' s Net Margin % Range Over the Past 10 Years
Min: -56.49  Med: -23.14 Max: 13.13
Current: -14.74
-56.49
13.13
ROE % -26.36
CSII's ROE % is ranked lower than
67% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. CSII: -26.36 )
Ranked among companies with meaningful ROE % only.
CSII' s ROE % Range Over the Past 10 Years
Min: -99.5  Med: -47.59 Max: 10
Current: -26.36
-99.5
10
ROA % -19.31
CSII's ROA % is ranked lower than
66% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. CSII: -19.31 )
Ranked among companies with meaningful ROA % only.
CSII' s ROA % Range Over the Past 10 Years
Min: -58.12  Med: -30.3 Max: 6.68
Current: -19.31
-58.12
6.68
ROC (Joel Greenblatt) % -64.93
CSII's ROC (Joel Greenblatt) % is ranked lower than
65% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. CSII: -64.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CSII' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4509.29  Med: -177.88 Max: 88.2
Current: -64.93
-4509.29
88.2
3-Year Revenue Growth Rate 4.60
CSII's 3-Year Revenue Growth Rate is ranked higher than
53% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. CSII: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CSII' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7 Max: 23.9
Current: 4.6
0
23.9
3-Year EBITDA Growth Rate 16.90
CSII's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. CSII: 16.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CSII' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -27.5 Max: 79.4
Current: 16.9
0
79.4
3-Year EPS without NRI Growth Rate 15.70
CSII's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. CSII: 15.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CSII' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.2  Med: -9.05 Max: 81.2
Current: 15.7
-66.2
81.2
GuruFocus has detected 3 Warning Signs with Cardiovascular Systems Inc $CSII.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CSII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CSII Guru Trades in Q1 2016

Steven Cohen 102,200 sh (New)
Paul Tudor Jones 10,900 sh (New)
Mario Gabelli 36,300 sh (+3.13%)
Mairs and Power 246,202 sh (unchged)
Jim Simons Sold Out
» More
Q2 2016

CSII Guru Trades in Q2 2016

Steven Cohen 403,824 sh (+295.13%)
Mario Gabelli 36,400 sh (+0.28%)
Paul Tudor Jones Sold Out
Mairs and Power 121,202 sh (-50.77%)
» More
Q3 2016

CSII Guru Trades in Q3 2016

Jim Simons 174,100 sh (New)
Paul Tudor Jones 13,000 sh (New)
Mario Gabelli 36,400 sh (unchged)
Mairs and Power 76,002 sh (-37.29%)
Steven Cohen 171,100 sh (-57.63%)
» More
Q4 2016

CSII Guru Trades in Q4 2016

John Hussman 117,000 sh (New)
Paul Tudor Jones 18,806 sh (+44.66%)
Mario Gabelli 36,400 sh (unchged)
Steven Cohen Sold Out
Mairs and Power 75,762 sh (-0.32%)
Jim Simons 131,100 sh (-24.70%)
» More
» Details

Insider Trades

Latest Guru Trades with CSII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:VASC, NAS:MDXG, NAS:KTWO, NYSE:ITGR, NAS:SPNC, NAS:CNMD, NAS:OFIX, NAS:BABY, OTCPK:IOBCF, NYSE:CRY, NAS:INGN, NAS:GNMK, NAS:ARAY, OTCPK:MZRTF, NYSE:IVC, NAS:XENT, NAS:AXGN, NAS:EXAC, NAS:ELOS, NAS:CYNO » details
Traded in other countries:R7Y1.Germany,
Cardiovascular Systems Inc is a medical technology company. It is engaged in developing, manufacturing, and marketing devices for the treatment of vascular diseases.

Cardiovascular Systems Inc was incorporated as Replidyne, Inc. in Delaware in 2000. It is a medical technology company. The Company is engaged in developing, manufacturing, and marketing devices for the treatment of vascular diseases. It treats patients suffering from peripheral and coronary arterial diseases, including those with arterial calcium, the difficult arterial disease to treat. The Company is committed to clinical rigor, constant innovation and a defining drive to set the industry standard to deliver safe and effective medical devices that improve lives of patients facing this difficult disease state. Its product s include Diamondback 360 Peripheral, Predator 36, Stealth 360, Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral. It competes with Abbott Laboratories, Boston Scientific, Cook Medical, Johnson & Johnson, BARD, and Medtronic. It also competes against manufacturers of atherectomy catheters including Medtronic, Spectranetics, Boston Scientific and Philips. The Company held approximately 46 issued U.S. patents and have approximately 39U.S.patent applications pending, as well as approximately 203 issued or granted foreign patents and approximately 148 foreign patent applications, each of which corresponds to aspects of its U.S. patents and applications. The Company have received 18 federal registrations in the U.S. Patent and Trademark Office of certain marks, including Diamondback, a first CSI, second CSI, Predator 360, Stealth 360, a first CSI logo, a second CSI logo, Lumen Library, Viper Wire, Viper Wire Advance, Viper slide, Viper Track, Viper Caddy, Stealth 360, a first Diamondback 360, a second Diamondback 360, Diamondback 360 (Stylized) Logo, and Stay A Step Ahead of PAD.

Ratios

vs
industry
vs
history
PB Ratio 8.18
CSII's PB Ratio is ranked lower than
84% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. CSII: 8.18 )
Ranked among companies with meaningful PB Ratio only.
CSII' s PB Ratio Range Over the Past 10 Years
Min: 0.18  Med: 5.58 Max: 14.5
Current: 8.18
0.18
14.5
PS Ratio 4.70
CSII's PS Ratio is ranked lower than
68% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. CSII: 4.70 )
Ranked among companies with meaningful PS Ratio only.
CSII' s PS Ratio Range Over the Past 10 Years
Min: 0.24  Med: 2.36 Max: 7.39
Current: 4.7
0.24
7.39
Price-to-Free-Cash-Flow 165.49
CSII's Price-to-Free-Cash-Flow is ranked lower than
95% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. CSII: 165.49 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CSII' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 139.23  Med: 151.46 Max: 173.75
Current: 165.49
139.23
173.75
Price-to-Operating-Cash-Flow 117.36
CSII's Price-to-Operating-Cash-Flow is ranked lower than
97% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. CSII: 117.36 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CSII' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 98.69  Med: 107.37 Max: 123.16
Current: 117.36
98.69
123.16
Current Ratio 3.80
CSII's Current Ratio is ranked higher than
69% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. CSII: 3.80 )
Ranked among companies with meaningful Current Ratio only.
CSII' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.91 Max: 17.17
Current: 3.8
1.27
17.17
Quick Ratio 3.30
CSII's Quick Ratio is ranked higher than
72% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. CSII: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
CSII' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 3.36 Max: 17.17
Current: 3.3
1.18
17.17
Days Inventory 170.61
CSII's Days Inventory is ranked lower than
66% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. CSII: 170.61 )
Ranked among companies with meaningful Days Inventory only.
CSII' s Days Inventory Range Over the Past 10 Years
Min: 37.97  Med: 113.08 Max: 170.61
Current: 170.61
37.97
170.61
Days Sales Outstanding 48.09
CSII's Days Sales Outstanding is ranked higher than
77% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. CSII: 48.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
CSII' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.38  Med: 55.96 Max: 61.98
Current: 48.09
47.38
61.98
Days Payable 74.71
CSII's Days Payable is ranked higher than
61% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. CSII: 74.71 )
Ranked among companies with meaningful Days Payable only.
CSII' s Days Payable Range Over the Past 10 Years
Min: 74.71  Med: 106.82 Max: 116.18
Current: 74.71
74.71
116.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.40
CSII's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. CSII: -10.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CSII' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -242.8  Med: -47.9 Max: -10.4
Current: -10.4
-242.8
-10.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 27.53
CSII's Price-to-Net-Cash is ranked lower than
68% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. CSII: 27.53 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CSII' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.54  Med: 11.98 Max: 231.2
Current: 27.53
0.54
231.2
Price-to-Net-Current-Asset-Value 12.04
CSII's Price-to-Net-Current-Asset-Value is ranked lower than
73% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 6.59 vs. CSII: 12.04 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CSII' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.53  Med: 6.88 Max: 27.54
Current: 12.04
0.53
27.54
Price-to-Tangible-Book 8.56
CSII's Price-to-Tangible-Book is ranked lower than
76% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. CSII: 8.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CSII' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.52  Med: 6.15 Max: 12.81
Current: 8.56
0.52
12.81
Price-to-Median-PS-Value 2.01
CSII's Price-to-Median-PS-Value is ranked lower than
91% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. CSII: 2.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CSII' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.06 Max: 2.95
Current: 2.01
0.3
2.95
Earnings Yield (Greenblatt) % -3.66
CSII's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. CSII: -3.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CSII' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.81  Med: 32 Max: 5408.1
Current: -3.66
-3.81
5408.1

More Statistics

Revenue (TTM) (Mil) $192.8
EPS (TTM) $ -0.87
Beta2.32
Short Percentage of Float3.90%
52-Week Range $7.50 - 29.70
Shares Outstanding (Mil)32.60

Analyst Estimate

Jun17 Jun18
Revenue (Mil $)
EPS ($) -0.08 0.15
EPS without NRI ($) -0.08 0.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CSII

Headlines

Articles On GuruFocus.com
Stocks Mario Gabelli Has Bought for 2 Quarters Jun 20 2016 
Stocks Bill Frels Keeps On Buying Nov 17 2015 
Mairs & Power Small Cap Fund Comments on Cardiovascular Systems Oct 20 2014 
Mairs & Power Small Cap Fund Q3 2014 Commentary Oct 20 2014 
Weekly CEO Sells Highlight: Google Inc, Infromatica Corp, Deckers Outdoor Corp and Cardiovascular Sy Aug 14 2011 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 13,170 Shares Nov 19 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 39,330 Shares Nov 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Nov 12 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) CFO Laurence L Betterley sells 5,663 Shares May 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Medtronic Poised on Strong Fundamentals Despite Several Woes Feb 24 2017
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise Feb 24 2017
Align Expands Internationally with Dental Couture Buyout Feb 23 2017
Henry Schein Inks Agreement for Rijuven's CardioSleeve Feb 23 2017
CARDIOVASCULAR SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 22 2017
Cardiovascular Systems Announces Healthcare Veteran Martha Goldberg Aronson Joins Board of Directors Feb 21 2017
Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View Feb 21 2017
Ecolab's (ECL) Earnings, Revenues Miss Estimates in Q4 Feb 21 2017
Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View Feb 21 2017
Henry Schein to Acquire SAS to Strengthen Dental Offerings Feb 21 2017
Cardiovascular Systems Releases 1-Year Results from COAST IDE Study in Late-Breaking Presentation at... Feb 20 2017
GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y Feb 17 2017
Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT Feb 17 2017
LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View Feb 16 2017
Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View Feb 16 2017
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss Feb 16 2017
Genomic Health (GHDX) Earnings Surpass Estimates in Q4 Feb 15 2017
ETFs with exposure to Cardiovascular Systems, Inc. : February 14, 2017 Feb 14 2017
Medtronic (MDT) Adds New Tools, Expands Coronary Suite Feb 14 2017
Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)